Anidulafungin: Is it a promising option in the treatment of pediatric invasive fungal infections?

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 3, 2011, Pages 339-346

  Tapisiz, Anil ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

anidulafungin; Aspergillus; Candida; children

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; CENTRAL NERVOUS SYSTEM INFECTION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ESOPHAGUS CANDIDIASIS; FACE ERYTHEMA; FEBRILE NEUTROPENIA; FEVER; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOKALEMIA; HYPOTENSION; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LEUKOPENIA; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MUCOCUTANEOUS CANDIDIASIS; NAUSEA; NEUTROPENIA; NONHUMAN; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SYSTEMIC MYCOSIS; TREATMENT PLANNING;

ADULT; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS, INVASIVE; CHILD; DRUG INTERACTIONS; DRUG RESISTANCE, FUNGAL; DRUG THERAPY, COMBINATION; ECHINOCANDINS; HUMANS;

EID: 79952969348     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.7     Document Type: Review

References (71)

1. Blyth CC, Chen SC, Slavin MA et al. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics 123, 1360-1368 (2009).
2. Zaoutis TE, Prasad PA, Localio AR et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin. Infect. Dis. 51, 38-45 (2010).
3. Neu N, Malik M, Lunding A et al. Epidemiology of candidemia at a Children's hospital, 2002 to 2006. Pediatr. Infect. Dis. J. 28, 806-809 (2009).
4. Charlier C, Hart E, Lefort A et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J. Antimicrob. Chemother. 57, 384-410 (2006). (Pubitemid 43240191)
5. Pannaraj PS, Walsh TJ, Baker CJ. Advances in antifungal therapy. Pediatr. Infect. Dis. J. 24, 921-922 (2005).
6. Lass-Flörl C. Invasive fungal infections in pediatric patients: a review focusing on antifungal therapy. Expert Rev. Anti Infect. Ther. 8, 127-135 (2010).
7. Messer SA, Jones RN, Moet GJ, Kirby JT, Castanheira M. Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008). J. Clin. Microbiol. 48, 2984-2987 (2010).
8. Messer SA, Moet GJ, Kirby JT, Jones RN. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J. Clin. Microbiol. 47, 1942-1946 (2009).
9. Pfaller MA, Hollis R, Goldstein BP, Messer S, Diekema D, Henkel T. In vitro activity of anidulafungin and other agents against esophageal candidiasisassociated isolates from a Phase 3 clinical trial. J. Clin. Microbiol. 48, 2613-2614 (2010).
10. Hof H, Dietz A. Antifungal activity of anidulafungin, a product of Aspergillus nidulans, against Aspergillus nidulans. Int. J. Antimicrob. Agents 33, 285-286 (2009).
11. Denning DW. Echinocandin antifungal drugs. Lancet 362, 1142-1151 (2003). (Pubitemid 37222342)
12. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, Ostrosky-Zeichner L. In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob. Agents Chemother. 48, 1912-1915 (2004). (Pubitemid 38544413)
13. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J. Clin. Microbiol. 43, 5425-5427 (2005). (Pubitemid 41612308)
14. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. 36, 198-202 (1998). (Pubitemid 28047458)
15. Diekema DJ, Messer SA, Boyken LB et al. In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J. Clin. Microbiol. 47, 3170-3177 (2009).
16. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46, 2620-2629 (2008).
17. Perlin DS. Resistance to echinocandinclass antifungal drugs. Drug Resist. Updat. 10, 121-130 (2007).
18. Garcia-Effron G, Chua DJ, Tomada JR et al. Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob. Agents Chemother. 54, 2225-2227 (2010).
19. Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-b-d-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53, 3690-3699 (2009).
20. Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J. Clin. Pharmacol. 44, 590-598 (2004). (Pubitemid 38668021)
21. Nguyen KT, Ta P, Hoang BT et al. Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. Antimicrob. Agents Chemother. 53, 3347-3352 (2009).
22. Benjamin DK Jr, Driscoll T, Seibel NL et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob. Agents Chemother. 50, 632-638 (2006). (Pubitemid 43190976)
23. Dowell JA, Stogniew M, Krause D, Damle B. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J. Clin. Pharmacol. 47, 461-470 (2007). (Pubitemid 46465954)
24. Damle B, Stogniew M, Dowell J. Pharmacokinetics and tissue distribution of anidulafungin in rats. Antimicrob. Agents Chemother. 52, 2673-2676 (2008). (Pubitemid 351915707)
25. Perkhofer S, Lass-Flörl C. Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination. Expert Opin. Investig. Drugs 18, 1393-1404 (2009).
26. Damle BD, Dowell JA, Walsky RL, Weber GL, Stogniew M, Inskeep PB. In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. Antimicrob. Agents Chemother. 53, 1149-1156 (2009).
27. Krause DS, Simjee AE, van Rensburg C et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis. 39, 770-775 (2004). (Pubitemid 39244288)
28. Reboli AC, Rotstein C, Pappas PG et al.; Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356, 2472-2482 (2007). (Pubitemid 46919773)
29. Pfizer, Inc. Final package insert for ERAXIS (anidulafungin) for injection. NY, USA (2006).
30. Dowell JA, Stogniew M, Krause D, Henkel T, Weston IE. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J. Clin. Pharmacol. 45, 227-233 (2005). (Pubitemid 40490447)
31. Dowell JA, Schranz J, Baruch A, Foster G. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J. Clin. Pharmacol. 45, 1373-1382 (2005). (Pubitemid 41642440)
32. Dowell JA, Stogniew M, Krause D, Henkel T, Damle B. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. J. Clin. Pharmacol. 47, 305-314 (2007). (Pubitemid 46294710)
33. Eschenauer G, Depestel DD, Carver PL. Comparison of echinocandin antifungals. Ther. Clin. Risk Manag. 3, 71-97 (2007).
34. Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin. Infect. Dis. 43, 215-222 (2006).
35. Philip A, Odabasi Z, Rodriguez J et al. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob. Agents Chemother. 49, 3572-3574 (2005). (Pubitemid 41060623)
36. Pfaller MA, Diekema DJ, Boyken L et al. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob. Agents Chemother. 49, 4795-4797 (2005). (Pubitemid 41552623)
37. Krause DS, Reinhardt J, Vazquez JA et al.; Anidulafungin Invasive Candidiasis Study Group. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob. Agents Chemother. 48, 2021-2024 (2004). (Pubitemid 38691592)
38. Kett DH, Cubillos GF. Anidulafungin in the treatment of patients with invasive candidiasis. Int. J. Antimicrob. Agents 32, 99-102 (2008).
39. Cheung C, Guo Y, Gialanella P, Feldmesser M. Development of candidemia on caspofungin therapy: a case report. Infection 34, 345-348 (2006). (Pubitemid 44968928)
40. Pfaller MA, Diekema DJ, Gibbs DL et al.; Global Antifungal Surveillance Group. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J. Clin. Microbiol. 46, 842-849 (2008). (Pubitemid 351379967)
41. Pfaller MA, Boyken L, Hollis RJ et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46, 150-156 (2008).
42. Sarvikivi E, Lyytikäinen O, Soll DR et al. Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J. Clin. Microbiol. 43, 2729-2735 (2005). (Pubitemid 40827946)
43. van Asbeck E, Clemons KV, Martinez M, Tong AJ, Stevens DA. Significant differences in drug susceptibility among species in the Candida parapsilosis group. Diagn. Microbiol. Infect. Dis. 62, 106-109 (2008).
44. Ghannoum MA, Chen A, Buhari M et al. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit. Clin. Microbiol. Infect. 15, 274-279 (2009).
45. Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandin- and multiazoleresistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob. Agents Chemother. 49, 767-769 (2005). (Pubitemid 40175691)
46. Silva AP, Miranda IM, Lisboa C, Pina-Vaz C, Rodrigues AG. Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital. J. Clin. Microbiol. 47, 2392-2397 (2009).
47. de Toro M, Torres MJ, Maite R, Aznar J. Characterization of Candida parapsilosis complex isolates. Clin. Microbiol. Infect. 17(3), 418-424 (2010).
48. Tumbarello M, Posteraro B, Trecarichi EM et al. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J. Clin. Microbiol. 45, 1843-1850 (2007). (Pubitemid 46933916)
49. Jacobson MJ, Piper KE, Nguyen G, Steckelberg JM, Patel R. In vitro activity of anidulafungin against Candida albicans biofilms. Antimicrob. Agents Chemother. 52, 2242-2243 (2008). (Pubitemid 351758568)
50. Katragkou A, Chatzimoschou A, Simitsopoulou M et al. Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. Antimicrob. Agents Chemother. 52, 357-360 (2008).
51. Kucharíková S, Tournu H, Holtappels M, Van Dijck P, Lagrou K. In vivo efficacy of anidulafungin against Candida albicans mature biofilms in a novel rat model of catheter-associated candidiasis. Antimicrob. Agents Chemother. 54(10), 4474-4475 (2010).
52. Sobel JD, Revankar SG. Echinocandins - first-choice or first-line therapy for invasive candidiasis? N. Engl. J. Med. 356, 2525-2526 (2007). (Pubitemid 46919781)
53. Pappas G, Ierodiakonou V, Falagas ME. Lost in translation: differences in antimicrobial indication approval policies between the United States and Europe. Clin. Ther. 31, 1595-1603 (2009).
54. Kang CI, Rouse MS, Mandrekar JN, Steckelberg JM, Patel R. Anidulafungin treatment of Candida central nervous system infection in a murine model. Antimicrob. Agents Chemother. 53, 3576-3578 (2009).
55. Falcone M, Accarpio F, Venditti M et al. Septic bilateral pulmonary candidiasis successfully treated with anidulafungin therapy in two patients with peritoneal carcinomatosis. J. Antimicrob. Chemother. 65(10), 2266-2267 (2010).
56. Krause DS, Simjee AE, van Rensburg C et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis. 39, 770-775 (2004). (Pubitemid 39244288)
57. Vazquez JA, Schranz JA, Clark K, Goldstein BP, Reboli A, Fichtenbaum C. A Phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. J. Acquir. Immune Defic. Syndr. 48, 304-309 (2008).
58. Pfaller MA, Hollis R, Goldstein BP, Messer S, Diekema D, Henkel T. In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a Phase 3 clinical trial. J. Clin. Microbiol. 48, 2613-2614 (2010).
59. Andes D, Diekema DJ, Pfaller MA et al. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob. Agents Chemother. 52, 539-550 (2008). (Pubitemid 351170826)
60. Krishnan-Natesan S, Manavathu EK, Cutright JL, Chandrasekar PH. Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model. Int. J. Antimicrob. Agents 36, 33-36 (2010).
61. Petraitis V, Petraitiene R, Groll AH et al. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 42, 2898-2905 (1998). (Pubitemid 28501223)
62. Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob. Agents Chemother. 52, 321-328 (2008).
63. Spreghini E, Orlando F, Santinelli A et al. Anidulafungin in combination with amphotericin B against Aspergillus fumigatus. Antimicrob. Agents Chemother. 53, 4035-4039 (2009).
64. Perkhofer S, Jost D, Dierich MP, Lass-Flörl C. Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. Antimicrob. Agents Chemother. 52, 1873-1875 (2008). (Pubitemid 351614693)
65. van de Sande WW, Mathot RA, ten Kate MT et al. Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin. Antimicrob. Agents Chemother. 53, 2005-2013 (2009).
66. Petraitis V, Petraitiene R, Hope WW et al. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose-dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob. Agents Chemother. 53, 2382-2391 (2009).
67. US FDA Press Release: FDA Approves New Treatment for Fungal Infections www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2006/ucm108602. htm
68. European Medicines Agency (EMA): Ecalta www.ema.europa.eu/ema/index. jsp-curl=pages/medicines/human/ medicines/000788/human-med-000751. jsp&murl=menus/medicines/medicines. jsp&mid=WC0b01ac058001d124
69. Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis www.clinicaltrials.gov/ct2/results-term = A8851009
70. Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects www.clinicaltrials.gov/ct2/results-term = A1501095
71. Study To Assess The Safety, Pharmacokinetics, And Evaluate The Response To Anidulafungin When Treating Children With Invasive Candidiasis www.clinicaltrials.gov/ct2/results-term = A8851008.